On contrary, long-term use of βAR blockers have been found to be associated with small improvement in lung function and lower prevalence of respiratory adverse events in CHF with comorbidity of COPD or asthma10, 31, 32. This evidence concerns the gene ADRB2 and congestive heart failure.